Acorda Therapeutics, Inc. (ACORQ)

Market Cap	12.42K
Revenue (ttm)	115.66M
Net Income (ttm)	-263.43M
Shares Out	1.24M
EPS (ttm)	-212.10
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,600
Open	0.0135
Previous Close	n/a
Day's Range	0.0100 - 0.0135
52-Week Range	0.0100 - 18.0000
Beta	1.69
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2024

About ACORQ

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson’s disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. f...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 10, 2006
• Employees: 102
• Stock Exchange: OTCMKTS
• Ticker Symbol: ACORQ
• Website: https://www.acorda.com

Financial Performance

In 2023, ACORQ's revenue was $117.63 million, a decrease of -0.79% compared to the previous year's $118.57 million. Losses were -$252.85 million, 283.6% more than in 2022.

Financial numbers in USD